Crucell Terug naar discussie overzicht

Pevion Biotech Information

1. [verwijderd] 21 april 2006 18:58

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Al bekend?
   
   Pevion Biotech
   
   Dr. Jaap Goudsmit is new member to Board of Directors
   
   Bern, April 6th, 2006 - Dr. Jaap Goudsmit is Crucell´s Chief Scientific Officer and is responsible for all R&D activities. Prior to joining Crucell, Dr Goudsmit held various positions at the Academic Medical Center at the University of Amsterdam, and was Chairman of the Research Institute for Infectious Diseases and the Institute for Science Education. Dr Goudsmit has also taught and been a fellow at a number of institutions, such as the National Institutes of Health and New York University. He was founding Chariman of the Scientific Advisory Committee of the International AIDS Vaccine Initiative (IAVI) and the founding Co-Chair of the European Vaccine Effort against HIV/AIDS (EuroVac). In July 2003, Dr Goudsmit was appointed Chairman of the Board of the AIDS Foundation East-West, a NGO focused on AIDS prevention in the countries of the former Soviet Union. Since 1989 he has been a professor at the University of Amsterdam and the Academic Medical Center. He holds a medical degree and a PhD from the University of Amsterdam
   
2. [verwijderd] 21 april 2006 19:10

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   www.swissbiotechassociation.ch/files/...
   
   www.pevion.com/content/page-news.asp?...
3. [verwijderd] 21 april 2006 20:12

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   mcking schreef:

   www.swissbiotechassociation.ch/files/...
   
   www.pevion.com/content/page-news.asp?...
   

   Zie ook: www.iex.nl/forum/topic.asp?forum=228&...
   
   Mooi gevonden go!
   gr.
4. [verwijderd] 16 augustus 2006 10:18

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Vaccine Candidate For Leishmaniasis
   Carbohydrate-based formulation shows early promise in mouse tests
   Stu Borman
   A new type of carbohydrate vaccine candidate has been developed for leishmaniasis, a protozoan tropical disease that causes serious disfigurement and an estimated 60,000 deaths per year.
   
   There are currently no effective vaccines, but Peter H. Seeberger's group at the Swiss Federal Institute of Technology, Zurich, and colleagues at the Swiss Tropical Institute, Basel, and Pevion Biotech, Bern, have now developed a promising candidate (ACS Chem. Biol. 2006, 1, 161). They prepared synthetic carbohydrates resembling a leishmania antigen, made them immunologically active by linking them to both a phospholipid and a flu-virus coat protein, and then incorporated the conjugate into immunostimulating reconstituted influenza virosomes (IRIVs, liposomes with virus-derived lipid membranes).
   
   The formulations elicited a potentially long-lived (T-cell-dependent) antibody response in mice, and the antibodies recognize and react with native leishmania antigens. The results represent the first evidence that IRIVs have “great potential for the design of safe and effective synthetic carbohydrate vaccines,” the researchers write. Such vaccines "should find application for diseases including bacterial, viral, and parasitic infections and cancer," they add.
   
   Chemical & Engineering News
   ISSN 0009-2347
   Copyright © 2006 American Chemical Society
   pubs.acs.org/cen/news/84/i18/8418carb...
5. [verwijderd] 16 augustus 2006 10:34

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ook met gebruik Virosome technologie:
   
   Mymetics Announces NIH Plan To Test HIV-AIDS Vaccine Candidate In Non-Human Primate Model
   Main Category: HIV / AIDS News
   Article Date: 12 Mar 2006 - 0:00am (PDT)
   
   Mymetics Corporation (OTC: MYMX) announced today that the National Institutes of Health (NIH) has agreed to initiate testing of the Company's proprietary HIV-AIDS mucosal prophylactic vaccine candidate. The preclinical study will test Mymetics' vaccine in a non-human primate model. This study will take place in parallel to Mymetics' ongoing preclinical trial in another primate model. Mymetics' study was recently initiated in collaboration with the Cochin Institute (Paris, France), the Institute of Laboratory Animal Science of the Chinese Academy of Medical Sciences and the Faculty of Laboratory Animal Sciences of the Peking Union Medical College in Beijing (Republic of China).
   
   Mymetics also announced that the Company will present results of an earlier-stage preclinical study at the Keystone HIV Vaccines symposium being held from March 27 - April 2 in Keystone, Colorado. In this earlier study, Mymetics' vaccine elicited antibodies in the blood and other important anatomical compartments, such as internal mucosal surfaces, considered to be primary HIV entry sites. The mucosal antibodies showed high potency in vitro at inhibiting transcytosis of laboratory and primary HIV viruses from different HIV clades (strains), including those prevalent in Western countries and in Africa and parts of Asia. The Company will announce detailed results during the Keystone meeting.
   
   Dr. Sylvain Fleury, Ph.D., Mymetics' Chief Scientific Officer, commented, "We are extremely pleased that the NIH, an acknowledged world leader in supporting various vaccine research programs, has agreed to initiate their own preclinical study, qualifying our latest vaccine candidate as 'very promising [and worthy of] a thorough evaluation.' In the Company's concurrent trials, we will seek to confirm the results of the previous preclinical study demonstrating production of high levels of antibodies. If successful, we will then conduct a challenge study to determine the ability of these antibodies to protect against HIV in the primate models."
   
   Dr. Fleury continued, "The first results of the primate trials can be expected by the first quarter of 2007. Pending positive findings, we will then proceed to file with the FDA to begin pilot human clinical testing."
   
   Mymetics' HIV-AIDS prophylactic vaccine candidate program combines the Company's HIV-1 gp41-based immunogen expertise with virosome technology developed by Pevion Biotech AG (Switzerland), a spin-off from Berna AG and Bachem AG. Virosome-based vaccines are market-approved, stable lipidic structures that act as carriers for peptides or proteins toward which an immune protection is desired. Virosomes have a high safety profile with few side effects and have already been distributed by Pevion Biotech AG and administered to millions of people around the world.
   
   www.medicalnewstoday.com/medicalnews....
6. [verwijderd] 16 augustus 2006 11:13

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   CRUCELL FORM 20-F
   
   LIST OF SUBSIDIARIES OF CRUCELL N.V. as per June 29, 2006
   
   Name
   
   Residence Ownership %
   
   Crucell Holland B.V.
   Leiden, NL 100%
   
   U-BySis B.V.
   Leiden, NL 100%
   
   Chromagenics B.V.
   Amsterdam, NL 100%
   
   Berna Biotech AG
   Bern, CH 100%
   
   Istituto Sieroterapico Berna
   Milano, IT 100%
   
   Etna Biotech Spa
   Catania, IT 100%
   
   EtnaVax Holding AG
   Bern, CH 13%
   
   EtnaVax Spa
   Catania, IT 100%
   
   Berna Biotech Espana S.A.
   Madrid, ES 100%
   
   Rhein Biotech N.V.
   Maastricht, NL 92.7%
   
   Rhein Vaccines B.V.
   Maastricht, NL 100%
   
   Rhein Biotech GmbH
   Düsseldorf, DE 100%
   
   Rhein Minapharm
   Cairo, EG 3%
   
   Vida Rhein, S.A.
   Lisboa, PT 50%
   
   Pevion Biotech AG
   Bern, CH 50%
   
   Green Cross Vaccine Corporation
   Yongin, KR 100%
   
   www.secinfo.com/d11MXs.v1cD9.9.htm
7. [verwijderd] 16 augustus 2006 19:52

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   gocrucellgo schreef:

   Ook met gebruik Virosome technologie:
   
   Mymetics Announces NIH Plan To Test HIV-AIDS Vaccine Candidate In Non-Human Primate Model
   Main Category: HIV / AIDS News
   Article Date: 12 Mar 2006 - 0:00am (PDT)
   

   www.iex.nl/forum/topic.asp?forum=228&...
8. [verwijderd] 25 september 2006 18:14

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Pevion Biotech: Breast Cancer Vaccine Enters Clinical Development
   
   BERN, Switzerland, Sept. 25, 2006 – Pevion Biotech announced the start of phase I clinical testing of its virosome-based breast cancer vaccine. The multivalent vaccine will be tested for its safety and immunogenicity in patients overexpressing the HER-2/neu oncoprotein.
   
   
   
   Pevion Biotech, in collaboration with Bio Life Science (Vienna), has designed a therapeutic peptide vaccine to protect breast cancer patients from tumor recurrence following treatment of the primary tumor. The vaccine uses synthetic peptide antigens originating from the HER-2/neu oncoprotein, a protein almost exclusively present on cancerous cells, specifically breast cancer cells. The antigens were identified by Bio Life Science and combined with the market-approved adjuvant/carrier system PeviPROTM of Pevion Biotech. The companies performed intensive preclinical testing in vivo and ex vivo, where it was shown that the vaccine candidate was able to inhibit tumor cell growth and poses no safety concerns. In contrast to the current passive immunotherapy, the therapeutic breast cancer vaccine is intended to induce an active and longlasting immunity with reduced side effects.
   
   The phase I clinical trial is a single-center, randomized, placebo-controlled blind study being conducted at the Department of Medicine I of Medical University of Vienna, Austria. The participants in the study are 20 female volunteers with metastatic or unresectable, locally recurrent breast cancer, the cells of which moderately express the HER-2/neu oncoprotein. The primary aim of the study is to examine the safety and tolerability of the synthetic vaccine.Secondary objectives include assessments of the vaccine’s immunogenicity. In the course of the study, each subject will receive five vaccinations and will then be closely monitored. The study is scheduled for completion by mid-2007.
   
   Rinaldo Zurbriggen, CSO of Pevion Biotech, comments: “Today, cancer – specifically breast cancer – is regarded as a chronic disease. The goal of current therapies is management of the disease over a longer period of time. The passive immunization of breast cancer patients using monoclonal antibodies has meant a big step forward in this direction. Our active immunization approach by means of the body’s own immune system may help to manage the disease for an even longer period of time.”
   
   About breast cancer
   
   Breast cancer is the second leading cause of cancer death in women, exceeded only by lung cancer. It is estimated that in 2006 more than 200,000 new cases of invasive breast cancer will be diagnosed among women in the United States. Breast cancer incidence rates have continued to increase since 1980, although the rate of increase slowed in the 1990s, compared to the 1980s. Furthermore, in the more recent time period (1987-2000), breast cancer incidence rates have increased only in women aged 50 and older. The sequence of treatment usually is surgery, chemotherapy, radiation and hormonal (anti-estrogen) therapy. In recent years the genomic revolution has advanced the understanding of breast cancer biology and the molecular basis of antitumor immunity. Today, immunotherapies with monoclonal antibodies are a routine part of clinical care.
   
   About Pevion Biotech
   
   Pevion Biotech is a privately owned Swiss biopharmaceutical company focusing on the immunological treatment and prevention of infectious diseases and cancer. The company is a leading specialist in the development of efficient and safe vaccines based on its proprietary virosome-based technology platforms. Its technology is validated by two registered products which are marketed in over 45 countries. Pevion Biotech’s development pipeline includes, among others, vaccines against breast cancer, malaria and hepatitis C. Pevion Biotech was founded in 2002 as a joint venture company of Crucell (SWX: CRX ) and Bachem AG (SWX: BANB). Located in Bern, Switzerland, the company currently has a highly qualified staff of 21 scientists.
   
   For further questions, please contact:
   
   Peter Klein
   CEO
   Tel: 0041 31 980 62 12
   peter.klein@pevion.com
   www.pevion.com
   
   Pevion Biotech AG Rehhagstrasse 79 CH - 3018 Bern Switzerland
   Phone: + 41 (0)31 980 62 12 Fax: +41 (0)31 980 66 18
   E-Mail: peter.klein@pevion.com Web: www.pevion.com
   
   
9. gogogoo 25 september 2006 20:17

   auteur info

   • gogogoo

     Lid sinds: 28 feb 2006

     Laatste bezoek: 10 aug 2023

   • Aanbevelingen

     Ontvangen: 1600

     Gegeven: 808

   •    Aantal posts: 6.042

   Goed bericht.
   
   Welke stake heeft Crucell hier op dit moment in en gebruikt men nog technologieen van Berna cq. Crucell?
10. [verwijderd] 25 september 2006 21:26

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    gogogoo schreef:

    Goed bericht.
    
    Welke stake heeft Crucell hier op dit moment in en gebruikt men nog technologieen van Berna cq. Crucell?
    

    50 % en op basis van Berna technologie:
    
    Virosomes
    A proprietary delivery system with adjuvant properties, it shows excellent tolerability while stimulating both arms of the immune system. Used in two marketed vaccines, this is a versatile system that could potentially be used for the delivery of nucleic acids and therapeutics.
    
11. gogogoo 25 september 2006 21:31

    auteur info

    • gogogoo

      Lid sinds: 28 feb 2006

      Laatste bezoek: 10 aug 2023

    • Aanbevelingen

      Ontvangen: 1600

      Gegeven: 808

    •    Aantal posts: 6.042

    quote:

    gocrucellgo schreef:

    [quote=gogogoo]
    Goed bericht.
    
    Welke stake heeft Crucell hier op dit moment in en gebruikt men nog technologieen van Berna cq. Crucell?
    [/quote]
    
    50 % en op basis van Berna technologie:
    
    Virosomes
    A proprietary delivery system with adjuvant properties, it shows excellent tolerability while stimulating both arms of the immune system. Used in two marketed vaccines, this is a versatile system that could potentially be used for the delivery of nucleic acids and therapeutics.
    
    

    Had ik kunnen weten. Ben helaas geen biotech-expert en was in de veronderstelling dat Virosomes een generiek delivery systeem was. Had het wel al eens op de site van Berna zien staan.
    
    Bedankt voor de post.
12. [verwijderd] 25 september 2006 23:06

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hierbij pipeline Pevion met Phase I nog niet verwerkt van het breast cancer vaccin.
    

    Bijlage:
13. [verwijderd] 17 oktober 2006 12:31

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Vitamin D may help slow breast cancer -study
    Mon Oct 16, 2006 7:06pm ET
    
    By Patricia Reaney
    LONDON (Reuters) - High levels of vitamin D may help slow the progression of breast cancer, researchers suggested on Tuesday.
    In a small study of women with the illness they found that patients with early breast cancer had higher levels of the vitamin than those with more advanced disease.
    "Vitamin D levels are lower in women with advanced breast cancer than in early breast cancer," said Dr Carlo Palmieri, of Imperial College London.
    
    "It lends support to the idea that vitamin D has a role in the progression of breast cancer," he told Reuters.
    The researchers measured the amount of vitamin D in blood samples from 279 women with breast cancer. In 204 women, the disease was in its early stages. It was more advanced in the other 75.
    "We know from previous studies that breast cancer incidence is higher in women who live in higher latitudes and have less sun exposure," said Palmieri.
    Vitamin D, the so-called sunshine vitamin, is found in fortified milk and dairy products, cod liver oil and some fatty fish.
    The body produces vitamin D in the skin when it is exposed to sunlight. Laboratory tests have also shown that vitamin D can stop cancer cells from dividing.
    Breast cancer is the most common cancer in women, with more than a million cases detected worldwide each year, according to the International Agency for Research on Cancer (IARC) in Lyon, France. The earlier the cancer is detected and treated, the greater the chances of survival.
    Although the scientists do not know whether the low levels of vitamin D are a cause or a consequence of the cancer, their findings and the results of other studies suggest that low levels of vitamin D may be involved in the progression of early breast cancer to more advanced stages.
    "The next thing in this research is to try and understand the potential causes and mechanisms underlying these differences and the precise consequences at a molecular level," said Palmieri, who reported the finding in the Journal of Clinical Pathology.
    "We also need to look at the potential clinical implications of monitoring and maintaining high circulating vitamin D levels in breast cancer patients," he added in a statement.
    Breast cancer is treated with surgery and radiotherapy, chemotherapy and hormone treatment, or a combination of them, depending on the cancer and stage of the illness.
    Factors which can increase a woman's risk of breast cancer include having a mother or close relative with the disease, inherited mutations in the BRCA1 or BRCA2 genes, an early puberty, late menopause and not having any children.
    
    today.reuters.com/news/articlenews.as...
14. [verwijderd] 17 oktober 2006 12:40

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Virosome Technology
    
    Scope and technology principle
    One of the challenges in vaccine development is the creation of products that contain defined antigens of high purity and efficiently induce a protective immune response. Many antigen preparations are therefore supplemented with adjuvants to enhance the body’s immune response to the specific antigens. The most commonly used and approved adjuvants for human use are aluminium salt derivatives, which are known to cause adverse reactions such as irritation and inflammation at the injection site.
    Crucell’s patented virosome technology represents a new frontier in vaccinology, simultaneously improving the delivery of specific antigens to target immune cells, while bypassing the problems of conventional adjuvant-based vaccines.
    
    Based on liposomes, virosomes are tiny spherical vesicles made up of a mixture of synthetic and natural phospholipids holding the influenza virus surface proteins haemagglutinin (HA) and neuraminidase (NA). The HA and NA proteins provide the virosomes with properties that enable them to fuse with cells of the immune system. By embedding proteins of other human pathogens in the vesicles, virosomes can deliver their content - the vaccine specific antigens - directly to their targets, thereby stimulating the immune system.
    
    Availability
    Crucell’s patented virosome technology is a broadly applicable delivery system with prospective applications in areas beyond antigen-based vaccines, such as for the delivery of DNA/RNA or therapeutic drugs. Crucell has developed several methods which allow the absorption, the chemical binding and the incorporation of antigens onto/into virosomes. Therefore, virosomes offer a flexible new tool for developing novel prophylactic and even therapeutic vaccines for a variety of diseases. The virosome technology has been licensed for a number of indications on an exclusive basis to Pevion Biotech, a joint venture company with Bachem, and is still available for licensing for a number of infectious disease areas.
    
    Experience
    Crucell is the leading company in the development and production of virosomal vaccines. Virosomes are a market approved carrier system for the delivery of pharmaceutically or immunologically active substances.
    The technology has been used to develop Crucell’s product Inflexal® V, a trivalent seasonal influenza vaccine, as well as Epaxal®, a hepatis A vaccine.
    
    Virosome Technology is competitive
    Crucell’s patented virosome technology represents a new frontier in vaccinology, simultaneously improving the delivery of specific antigens to target immune cells, while bypassing the problems of conventional adjuvant-based vaccines. Thus virosomes stimulate antibody and cellular immune responses against the inserted antigens of a human pathogen.
    Virosomes are completely biodegradable and virosome-based vaccines do not exert the adverse reactions usually associated with adjuvant activity. Virosome formulations are compatible with intramuscular, intradermal and intranasal administration and are broadly applicable with almost any given antigen.
    
    Virosome Technology for highly immunogenic vaccines
    Two marketed products validate virosome technology: vaccines against hepatitis A and influenza. These products are registered for human use in more than 40 countries and have been administered to more than 30 million individuals. Virosomal vaccines have been shown to elicit highly protective immune responses with excellent safety profiles. Side effects are much less frequent after the application of virosomal vaccines compared to alum-precipitated antigens.
    
    Virosome based products from bench to clinic
    Crucell has fully operational GMP laboratories dedicated to virosomal products with integrated upstream and downstream capacities up to a scale of several 100,000 doses. These units are used to develop and produce any new virosomal formulation under strict cGMP conditions.
    

    Bijlage:
15. aossa 18 december 2006 18:25

    auteur info

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 27 mrt 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.622

    Pevion Biotech Announces Its Hepatitis C Vaccine Enters Clinical Phase I
    www.pharmalive.com/News/index.cfm?art...
    
    BERN, Switzerland, Dec. 18, 2006 – Pevion Biotech announced the start of phase I clinical testing of its virosome-based hepatitis C virus (HCV) vaccine. The therapeutic HCV vaccine is based on Pevion Biotech`s proprietary PeviPROTM and PeviTERTM technologies and will be tested for its safety and immunogenicity.
    
    Pevion Biotech has designed a therapeutic vaccine to treat patients who suffer from chronic hepatitis C virus infection. The vaccine is based on a combination of the PeviPROTM and PeviTERTM platforms using synthetic peptide antigens from the hepatitis C virus. Generally, a cellular immune response by cytotoxic T-lymphocytes (CTL) seems to be crucial in overcoming a hepatitis C virus infection. In-depth research in recent years has shown that the cellular immune response is even more effective when supported by helper T-cells. Pevion Biotech’s HCV vaccine candidate utilizes this effect inducing specific CTL responses (PeviTERTM) together with a supportive helper T cell response (PeviPROTM). This virosome-based technological combination in a single product represents a new generation of modular therapeutic vaccines.
    
    The phase I single-blind randomized placebo-controlled dose escalating study will be conducted under the lead of Professor Dr. med. Giuseppe Pantaleo at the Vaccine and Immunotherapy Center at the University Hospital in Lausanne, Switzerland, and comprises 30 healthy volunteers. The primary goal of the study is to examine the safety and tolerability of the synthetic vaccine. Secondary objectives include assessments of the vaccine’s immunogenicity.
    
    In the course of the study, each subject will receive multiple injections. During the clinical trial the volunteers will be closely monitored. The study is scheduled for completion by end of 2007.
    
    Peter Klein, CEO of Pevion Biotech, comments: “More than half of all HCV-infected patients do not experience significant long-term benefits from the current standard therapy using Interferon in combination with antiviral drugs. However, the very promising therapeutic vaccine approach of Pevion Biotech, which is aiming at a cellular immune-response, aims a new dimension of an effective therapy for patients suffering from chronic hepatitis C."
    
    About Hepatitis C
    
    According to the WHO, hepatitis C is a major cause of hepatitis and chronic liver disease, including cirrhosis and liver cancer. Globally, an estimated 170 million persons are chronically infected with HCV and 3 to 4 million persons are newly infected each year. HCV is spread primarily by direct contact with human blood. The major causes of HCV infection worldwide are the use of unscreened blood in transfusions, and re-use of needles and syringes that have not been adequately sterilized. Neither a prophylactic nor a therapeutic vaccine is currently available to prevent hepatitis C.
    
    About Pevion Biotech
    
    Pevion Biotech is a privately owned Swiss biopharmaceutical company focusing on the immunological treatment and prevention of infectious diseases and cancer. The company is a leading specialist in the development of efficient and safe vaccines based on its proprietary virosome-based technology platforms. Pevion Biotech’s technology PeviPROTM is approved by regulatory authorities and well established for prophylactic use. Further improvement of the wellaccepted and safe PeviPROTM vaccine technology led to the development of PeviTERTM, which represents Pevion Biotech’s technique for the accelerated development of therapeutic vaccines against chronic infectious diseases and cancer. Pevion Biotech’s development pipeline includes, among others, vaccines against HCV, breast cancer, malaria and candidiasis. Pevion Biotech was founded in 2002 as a joint venture company of Crucell N.V. (Euronext, NASDAQ: CRXL; SWX: CRX) and Bachem AG (SWX: BANB). Located in Bern, Switzerland, the company currently has a staff of 21 scientists.
    
    ============================
    Volgens IV-forum:
    www1.investorvillage.com/smbd.asp?mb=...
    
    Crucell/Pevion relationship:
    
    " Pevion Biotech was founded in 2002 as a joint venture company of Crucell N.V. (Euronext, NASDAQ: CRXL; SWX: CRX) and Bachem AG (SWX: BANB). "
    
    VIROSOME TECHNOLOGY:
    
    Crucell’s patented virosome technology is a broadly applicable delivery system with prospective applications in areas beyond antigen-based vaccines, such as for the delivery of DNA/RNA or therapeutic drugs. Crucell has developed several methods which allow the absorption, the chemical binding and the incorporation of antigens onto/into virosomes. Therefore, virosomes offer a flexible new tool for developing novel prophylactic and even therapeutic vaccines for a variety of diseases. The virosome technology has been licensed for a number of indications on an exclusive basis to Pevion Biotech, a joint venture company with Bachem, and is still available for licensing for a number of infectious disease areas.
    
    Crucell is the leading company in the development and production of virosomal vaccines. Virosomes are a market approved carrier system for the delivery of pharmaceutically or immunologically active substances.
    
    The technology has been used to develop Crucell’s product Inflexal® V, a trivalent seasonal influenza vaccine, as well as Epaxal®, a hepatis A vaccine.
    
    
16. diederique 18 december 2006 18:30

    auteur info

    • diederique

      Lid sinds: 01 mrt 2004

      Laatste bezoek: 06 mrt 2025

    • Aanbevelingen

      Ontvangen: 913

      Gegeven: 218

    •    Aantal posts: 8.547

    BERN, Switzerland, Dec. 18, 2006 – Pevion Biotech announced the start of phase I clinical testing of its virosome-based hepatitis C virus (HCV) vaccine. The therapeutic HCV vaccine is based on Pevion Biotech`s proprietary PeviPROTM and PeviTERTM technologies and will be tested for its safety and immunogenicity.
    
    en
    
    Biotech was founded in 2002 as a joint venture company of Crucell N.V. (Euronext, NASDAQ: CRXL; SWX: CRX) and Bachem AG (SWX: BANB). Located in Bern, Switzerland, the company currently has a staff of 21 scientists.
    
    Vraag:
    
    Waarom niet bekend gemaakt door de company uit Leiden?
    
    overigens goede deskresearch..........
    
    www.pevion.com/index.php?page=696
    
    www.pevion.com/images/content/Pevion_...
17. aossa 18 december 2006 18:33

    auteur info

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 27 mrt 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.622

    quote:

    diederique schreef:

    Vraag; Waarom niet bekend gemaakt door de company uit Leiden?

    Zijn nog niet op de hoogte gebracht door Pevion (?)
    Is eigenlijk een spinn-off van Berna Biotech (nu Crucell).
18. Mr sponge 18 december 2006 18:42

    auteur info

    • Mr sponge

      Lid sinds: 16 jan 2001

      Laatste bezoek: 28 mrt 2025

    • Aanbevelingen

      Ontvangen: 590

      Gegeven: 178

    •    Aantal posts: 2.485

    quote:

    gocrucellgo schreef:

    Hierbij pipeline Pevion met Phase I nog niet verwerkt van het breast cancer vaccin.
    
    

    Zie ik daar ook een fase 2 voor Malaria. Als er dus een van de 2 malaria vaccins het niet haalt is dat dus geen ramp... Men heeft immers een backup achter de hand. (Al is dit laatste vaccin maar voor 50% van Crucell).
19. aossa 18 december 2006 18:51

    auteur info

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 27 mrt 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.622

    Ownership Pevion Biotech by Crucell = 50%
    www.secinfo.com/d11MXs.v1cD9.9.htm
    
    En WOW ze hebben een MALARIA - VACCINE in de pipe-line (Clinic Phase2) zie *.pdf hiervoor en attachment.
    
    <Nu begrijp ik de grimlach van Brus ...>

    Bijlage:
20. diederique 18 december 2006 18:57

    auteur info

    • diederique

      Lid sinds: 01 mrt 2004

      Laatste bezoek: 06 mrt 2025

    • Aanbevelingen

      Ontvangen: 913

      Gegeven: 218

    •    Aantal posts: 8.547

    van betekenis:
    
    "In the course of the study, each subject will receive multiple injections. During the clinical trial the volunteers will be closely monitored. The study is scheduled for completion by end of 2007.
    
    Peter Klein, CEO of Pevion Biotech, comments: “More than half of all HCV-infected patients do not experience significant long-term benefits from the current standard therapy using Interferon in combination with antiviral drugs. However, the very promising therapeutic vaccine approach of Pevion Biotech, which is aiming at a cellular immune-response, aims a new dimension of an effective therapy for patients suffering from chronic hepatitis C."